Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
Azenta (Nasdaq: AZTA) has been chosen by the Crohn's & Colitis Foundation for sample management services for two key research initiatives: CAPTURE IBD and IBD SIRQC. These studies focus on pediatric and surgical care for Crohn's disease and ulcerative colitis. Azenta will handle sample processing, analysis, logistics, and storage. These efforts are part of the Foundation's IBD Plexus® platform, which aims to revolutionize research with well-phenotyped data and biosamples. CAPTURE IBD is a longitudinal study enrolling thousands of pediatric patients across 12 U.S. sites. IBD SIRQC targets 5,000 patients at 9 sites, focusing on surgical outcomes. Azenta's role is anticipated to advance understanding and treatment of these diseases.
- Azenta selected for high-profile clinical research projects, boosting credibility.
- Partnership with Crohn's & Colitis Foundation may lead to long-term collaborations.
- CAPTURE IBD and IBD SIRQC provide access to extensive, valuable data.
- Supporting CAPTURE IBD, which enrolls several thousand pediatric patients, showcasing large-scale involvement.
- IBD SIRQC aims to enroll 5,000 patients, indicating significant research contribution.
- Incorporation into IBD Plexus® platform, aligning with cutting-edge research.
- Potential financial burden from managing large-scale research cohorts.
- Risk of delays or complications in sample management impacting project timelines.
- Uncertain financial returns on investment in the short term.
Insights
The collaboration between Azenta and the Crohn's & Colitis Foundation for managing samples in two large-scale research cohorts, CAPTURE IBD and IBD SIRQC, holds potential for significant advancements in the study and treatment of Crohn's disease and ulcerative colitis. By providing centralized and high-quality sample management services, Azenta can ensure the robustness and reliability of the data collected from these studies, which are important for precision medicine.
CAPTURE IBD focuses on pediatric patients and aims to personalize treatment approaches, while IBD SIRQC targets surgical outcomes and long-term patient monitoring. This dual approach can provide comprehensive insights into both medical and surgical interventions, thus fostering a more holistic understanding of IBD management and treatment strategies.
Azenta's selection by the Crohn's & Colitis Foundation enhances its visibility and credibility in the sample management and biobanking sector. This partnership aligns well with Azenta's core competencies and could potentially open doors to further collaborations within the life sciences industry. By supporting high-profile research initiatives, Azenta can showcase its capabilities and maintain a competitive edge in a growing market.
Additionally, the focus on pediatric and surgical aspects of IBD can tap into specific market needs, potentially leading to enhanced reputation and business opportunities. Investors might see this as a strategic move that not only reinforces Azenta’s market position but also creates pathways for future revenue streams.
This collaboration is likely to have a positive financial impact on Azenta. By engaging in these pivotal studies, Azenta not only secures a reliable revenue stream from sample management services but also strengthens its brand with high-stakes research projects. Given the scale of the CAPTURE IBD and IBD SIRQC studies, the financial contribution from these projects could be substantial in the short term.
Furthermore, such partnerships often lead to long-term business relationships and opportunities for repeat engagements, which can provide consistent revenue. Investors should also consider the potential for positive publicity and increased investor confidence resulting from this high-profile collaboration.
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries
These studies are part of the Foundation's IBD Plexus® research ecosystem and data platform that redefines how the research community studies Crohn's disease and ulcerative colitis to advance next-generation discoveries and novel therapies. The platform offers a rich research ecosystem for academic and life science researchers, providing prospective, longitudinal, and well-phenotyped data linked to biosamples to accelerate answering high-impact, patient-prioritized questions, and drive a revolutionary approach toward faster cures.
CAPTURE IBD (Cohort for Pediatric Translational and Clinical Research in Inflammatory Bowel Disease) is a multi-center, longitudinal study designed to advance precision medicine in pediatric IBD. CAPTURE is looking to enroll several thousand pediatric patients at 12 participating sites in
IBD SIRQC (Surgical Innovation, Research, and Quality Collaborative) is the Foundation's first-ever surgical research initiative designed as a longitudinal surgical cohort that will track long-term surgery outcomes including post-procedure complications and disease recurrence. SIRQC is looking to enroll 5,000 patients at 9 participating sites in
"The integration of novel pediatric and surgical data and biosamples into the IBD Plexus platform is critical to advance understanding of the complexity of IBD and develop precision medicine strategies," said Angela Dobes, Senior Vice President, IBD Plexus, Crohn's & Colitis Foundation. "We selected Azenta to support our CAPTURE and SIRQC research initiatives because of their high-quality, centralized sample management services and strong customer support. We look forward to continuing the partnership."
"Azenta is delighted to be expanding our relationship with the Crohn's & Colitis Foundation by supporting these critical studies that have the potential to accelerate breakthroughs for the Crohn's and ulcerative colitis community," said Kathi Shea, Vice President and General Manager of Sample and Repository Services at Azenta. "Our support of the Foundation goes back many years supporting clinical trial samples using our core storage and GENEWIZ Multiomics & Synthesis Solutions. We are proud to have been selected to support this prestigious organization."
About Crohn's &Colitis Foundation
The Crohn's & Colitis Foundation is the leading nonprofit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis and improving the quality of life for the millions of Americans living with IBD. The Foundation's work is dramatically accelerating the research process, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public.
To learn more about the IBD Plexus® program, visit https://www.crohnscolitisfoundation.org/research/plexus
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington,
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
Azenta's use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-announces-collaboration-with-the-crohns--colitis-foundation-to-support-its-crohns-disease-and-ulcerative-colitis-clinical-research-302163828.html
SOURCE Azenta
FAQ
What is Azenta’s role in the Crohn's & Colitis Foundation research?
What are CAPTURE IBD and IBD SIRQC?
How many patients will be involved in CAPTURE IBD?
How many patients will IBD SIRQC enroll?
What is the significance of Azenta’s partnership with the Crohn's & Colitis Foundation?
